Santen Pharmaceutical Announces the Appointment of Naveed Shams, M.D., Ph.D. as the President and CEO
3/12/2013 9:39:52 AM
More...
|
Santen Pharmaceutical and Clearside Biomedical Enter Into Financing and Research Collaboration Agreements for Posterior Ocular Disease
1/31/2013 10:18:08 AM
More...
|
Eisai Company, Ltd. (ESALY.PK) and Santen Pharmaceutical Enter Into Option Agreement for New Ophthalmic Drugs
9/27/2012 4:14:34 PM
More...
|
Santen Pharmaceutical Nabs Japanese Co-Promotion Rights to Bayer HealthCare (BAY) and Regeneron Pharmaceuticals, Inc. (REGN)'s Eylea
5/8/2012 6:55:17 AM
More...
|
Santen Pharmaceutical to Buy Novagali Pharma for $136 Million
9/28/2011 6:50:17 AM
More...
|
Inspire Pharmaceuticals, Inc. (ISPH) Announces Launch of DIQUASTM by Santen Pharmaceutical in Japan
12/13/2010 8:45:16 AM
More...
|
Clinical Data, Inc. Licenses Adenosine A2A Agonist to Santen Pharmaceutical for Development of Ophthalmic Treatments
5/3/2010 9:30:50 AM
More...
|
Santen Pharmaceutical And Inspire Pharmaceuticals, Inc. (ISPH) Announce Approval of DIQUAS(TM) for Dry Eye Treatment in Japan
4/16/2010 11:42:28 AM
More...
|
Japan's Santen Pharmaceutical Licenses Glaucoma Drug to Merck & Co., Inc. (MRK) (JOBS)
4/15/2009 7:07:18 AM
More...
|
Bausch & Lomb (BOL), Santen Pharmaceutical Strike Licensing Agreement for IOL Development
3/3/2009 8:27:30 AM
More...
|
|